Table 5.
Parameters | Pre | Post | ANOVA | ||||
---|---|---|---|---|---|---|---|
Placebo | αSleep® | Placebo | αSleep® | Group | Time | G × T | |
Glucose (mg/dL) | 94 ± 8 a | 99 ± 11 a | 94 ± 8 a | 98 ± 8 a | F(1, 22) = 1.295 p = 0.267 |
F(1, 22) = 0.014 p = 0.908 |
F(1, 22) = 1.352 p = 0.257 |
AST (U/L) |
26 ± 5 a | 28 ± 5 a | 25 ± 5 a | 29 ± 4 a | F(1, 22) = 3.728 p = 0.066 |
F(1, 22) = 0.002 p = 0.965 |
F(1, 22) = 0.240 p = 0.629 |
ALT (U/L) |
25 ± 7 a | 28 ± 7 a | 25 ± 5 a | 29 ± 5 a | F(1, 22) = 1.932 p = 0.178 |
F(1, 22) = 0.165 p = 0.688 |
F(1, 22) = 0.225 p = 0.640 |
TC (mg/dL) |
210 ± 19 a | 212 ± 12 a | 211 ± 16 a | 213 ± 9 a | F(1, 22) = 0.171 p = 0.683 |
F(1, 22) = 0.535 p = 0.472 |
F(1, 22) = 0.011 p = 0.918 |
TG (mg/dL) |
120 ± 28 a | 125 ± 31 a | 121 ± 26 a | 119 ± 31 a,* | F(1, 22) = 0.015 p = 0.903 |
F(1, 22) = 1.913 p = 0.181 |
F(1, 22) = 5.894 p = 0.024 |
HDL (mg/dL) | 55.1 ± 6.8 a | 50.9 ± 6.5 a | 54.7 ± 6.5 a | 53.1 ± 6.1 a,* | F(1, 22) = 1.293 p = 0.268 |
F(1, 22) = 3.701 p = 0.067 |
F(1, 22) = 7.538 p = 0.012 |
LDL (mg/dL) | 138.6 ± 14.3 a | 148.2 ± 9.2 a | 139.5 ± 14.4 a | 148.2 ± 5.0 a | F(1, 22) = 4.030 p = 0.057 |
F(1, 22) = 0.247 p = 0.624 |
F(1, 22) = 0.247 p = 0.624 |
IL-6 (pg/mL) | 1.42 ± 0.32 a | 1.28 ± 0.49 a | 1.36 ± 0.41 a | 1.15 ± 0.52 a | F(1, 22) = 1.509 p = 0.232 |
F(1, 22) = 0.729 p = 0.402 |
F(1, 22) = 0.103 p = 0.751 |
TNF-α (pg/mL) | 0.53 ± 0.10 a | 0.58 ± 0.11 a | 0.58 ± 0.17 a | 0.57 ± 0.11 a | F(1, 22) = 0.244 p = 0.626 |
F(1, 22) = 0.310 p = 0.583 |
F(1, 22) = 0.949 p = 0.340 |
Data are presented as mean ± SD. Same superscript letters (a) indicate no significant differences among groups at the same time point. * indicates a significant effect (p < 0.05) after 2-week intervention compared with before intervention. AST, aspartate aminotransferase; ALT, alanine transaminase; TC, total cholesterol; TG, triacylglycerol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; IL-6, interleukin 6; TNF-α, tumor necrosis factor alpha.